User login
TOPLINE:
.
METHODOLOGY:
- Study population was all patients with type 1 diabetes in France who received a kidney transplant between 2000 and 2017.
- Among 2,393 patients, 327 were eligible for islet transplantation, including 47 who were actually transplanted with islets.
- The subjects were matched for factors including year of transplantation, recipient age, kidney function, and hemoglobin A1c.
TAKEAWAY:
- Those receiving islets along with the kidney transplant had a 53% lower risk of graft failure, compared with the kidney-alone group.
- Those receiving islet transplantation had a significantly higher estimated life expectancy during 10-year follow-up (9.61 vs. 8.85 years).
- At 1 year post islet transplant, there was an estimated 89.4% probability of graft survival and a 70.2% probability of achieving independence from insulin.
IN PRACTICE:
“Although islet transplantation has previously been shown to improve glycemic control, compared with conventional insulin therapy in recent clinical trials, little was known about its long-term impact on patient prognosis until now. ... These results are exciting and provide hope for people living with type 1 diabetes and kidney transplants.”
SOURCE:
Presented Sept. 17, 2023, at the European Society for Organ Transplantation (ESOT) Congress 2023 by Mehdi Maanaoui, MD, a nephrologist at the University of Lille (France).
LIMITATIONS:
Observational, potential for residual confounding.
DISCLOSURES:
Dr. Maanaoui reports no relevant financial relationships.
A version of this article first appeared on Medscape.com.
TOPLINE:
.
METHODOLOGY:
- Study population was all patients with type 1 diabetes in France who received a kidney transplant between 2000 and 2017.
- Among 2,393 patients, 327 were eligible for islet transplantation, including 47 who were actually transplanted with islets.
- The subjects were matched for factors including year of transplantation, recipient age, kidney function, and hemoglobin A1c.
TAKEAWAY:
- Those receiving islets along with the kidney transplant had a 53% lower risk of graft failure, compared with the kidney-alone group.
- Those receiving islet transplantation had a significantly higher estimated life expectancy during 10-year follow-up (9.61 vs. 8.85 years).
- At 1 year post islet transplant, there was an estimated 89.4% probability of graft survival and a 70.2% probability of achieving independence from insulin.
IN PRACTICE:
“Although islet transplantation has previously been shown to improve glycemic control, compared with conventional insulin therapy in recent clinical trials, little was known about its long-term impact on patient prognosis until now. ... These results are exciting and provide hope for people living with type 1 diabetes and kidney transplants.”
SOURCE:
Presented Sept. 17, 2023, at the European Society for Organ Transplantation (ESOT) Congress 2023 by Mehdi Maanaoui, MD, a nephrologist at the University of Lille (France).
LIMITATIONS:
Observational, potential for residual confounding.
DISCLOSURES:
Dr. Maanaoui reports no relevant financial relationships.
A version of this article first appeared on Medscape.com.
TOPLINE:
.
METHODOLOGY:
- Study population was all patients with type 1 diabetes in France who received a kidney transplant between 2000 and 2017.
- Among 2,393 patients, 327 were eligible for islet transplantation, including 47 who were actually transplanted with islets.
- The subjects were matched for factors including year of transplantation, recipient age, kidney function, and hemoglobin A1c.
TAKEAWAY:
- Those receiving islets along with the kidney transplant had a 53% lower risk of graft failure, compared with the kidney-alone group.
- Those receiving islet transplantation had a significantly higher estimated life expectancy during 10-year follow-up (9.61 vs. 8.85 years).
- At 1 year post islet transplant, there was an estimated 89.4% probability of graft survival and a 70.2% probability of achieving independence from insulin.
IN PRACTICE:
“Although islet transplantation has previously been shown to improve glycemic control, compared with conventional insulin therapy in recent clinical trials, little was known about its long-term impact on patient prognosis until now. ... These results are exciting and provide hope for people living with type 1 diabetes and kidney transplants.”
SOURCE:
Presented Sept. 17, 2023, at the European Society for Organ Transplantation (ESOT) Congress 2023 by Mehdi Maanaoui, MD, a nephrologist at the University of Lille (France).
LIMITATIONS:
Observational, potential for residual confounding.
DISCLOSURES:
Dr. Maanaoui reports no relevant financial relationships.
A version of this article first appeared on Medscape.com.